Boss cops 95% pay cut

Posted 11 May 2022 PM

Not so long ago they were the darlings of pharma - R&D bosses handsomely rewarded for their efforts during the pandemic - but last year's top earner has taken a dive from first place to tenth with a 95 per cent pay cut.

In 2020, Regeneron's President and Chief Scientific Officer George Yancopoulos raked in US$134 million, including US$100 million in stock awards.

To see the whole article, please login

Popular

Pharma headhunting gone wrong

Why doctors aren't seeing reps

$71B pharma revenue disappears

The hottest new career in pharma

Latest Jobs

Hospital Key Account Manager

Production Manager

Key Account Manager

Regulatory Affairs Officer

See all...

Pharma in Focus Jobs

Marketing & Communications (5)

Sales & Customer Relations (25)

Clinical & Medical, R&D (12)

Regulatory, Pharmacovigilance & QA (7)

Devices (1)

Hospital Devices Account Manager - Sydney

Other (24)

MORE NEWS

Email this article to a friend

From:

Subject

Friend's email

Message to go with the article

Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.

Skip password for now